Takeda licenses 2 drugs to NPS for as much as $80M

03/20/2013 | Genetic Engineering & Biotechnology News

Takeda Pharmaceutical granted NPS Pharmaceuticals complete global rights to develop and market its adult short bowel syndrome drug teduglutide and recombinant human parathyroid hormone 1-84, which is approved in Europe for post-menopausal osteoporosis. The deal covers all assets related to the two products. NPS will pay Takeda $50 million in common stock and a potential $30 million milestone fee.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care